Weekly Recap | WuXi Biologics -3.31%, a fade after early strengthWeekly Review·Nov 14, 2026 at 07:20 AMWXXWY-2.84%
Weekly Recap | WuXi Biologics +10.16%, biosimilars deal in focusWeekly Review·Nov 7, 2026 at 09:21 AMWXXWY-2.84%
Biosimilars Deal Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)Simplywall·Nov 6, 2026 at 08:32 AMFSNUY+0.54%WXXWY-2.84%
Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)Tip Ranks·Nov 5, 2026 at 12:27 AMWXXWY-2.84%02269-4.38%
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline | FSNUY Stock NewsStockTitan·Nov 1, 2026 at 10:47 PMFSNUY+0.54%WXXWY-2.84%
Chime and Copart Go Shopping While Washington Trains Its Sights on WuxiGlobal Report·Oct 28, 2026 at 03:46 AMCHYM+1.57%CPRT-0.52%
Weekly Recap | WuXi Biologics -8.04%, consensus target above spotWeekly Review·Oct 24, 2026 at 07:15 AMWXXWY-2.84%
WuXi Biologics consensus price target increased by 50.42% to $17.19MSN·Oct 22, 2026 at 07:02 PMWXXWY-2.84%02269-4.38%
WuXi Biologics Receives Jade Award for ESG LeadershipPUBT·Oct 21, 2026 at 06:43 AMWXXWY-2.84%02269-4.38%
WuXi Biologics Hosts Basel CRDMO+ Day for More Than 100 Industry Leaders and ExpertsPUBT·Oct 19, 2026 at 12:32 AMWXXWY-2.84%02269-4.38%
Cannabis Health Plays and Electronics Shadows: The Quiet Winners in Niche MarketsGlobal Report·Oct 13, 2026 at 10:15 AMTLRY-2.41%JBL-2.20%
Weekly Recap | WuXi Biologics -0.93%, highs then a fadeWeekly Review·Oct 10, 2026 at 08:14 AMWXXWY-2.84%
WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in EuropePR Newswire·Oct 9, 2026 at 07:43 AMWXXWY-2.84%02269-4.38%
How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment StorySimplywall·Oct 6, 2026 at 07:13 PMWXXWY-2.84%02269-4.38%
